We have signed an exclusive 12-month option agreement with Silk Road Therapeutics to acquire an orphan drug candidate for #Behçets Disease. The topical muco-adherent formulation of Pentoxifylline to treat oral ulcers has FDA Fast Track and Orphan Designation, positive Phase 2 data, and is positioned for potential 505(b)(2) regulatory pathway in the U.S. that can result in a much less expensive and much faster route to approval and commercialisation. There is a clear unmet medical need for an effective treatment for this rare disease, which currently has no cure. Behçet's Disease causes inflammation of blood vessels and tissues, resulting in debilitating symptoms, the most common being oral ulcers which impacts essential functions like eating, drinking and speaking. Read full announcement here: https://lnkd.in/ePAg63sW #POLB #Behçets #BehçetsDisease #raredisease #orphan
Poolbeg Pharma plc
Biotechnology Research
Committed to the development and commercialisation of innovative medicines. Ticker: POLB
About us
Poolbeg Pharma plc is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to fund the development of its robust pipeline of innovative products, thereby driving significant value creation. Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues. Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
- Website
-
https://www.poolbegpharma.com/
External link for Poolbeg Pharma plc
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- London
- Type
- Public Company
- Founded
- 2021
- Specialties
- cancer immunotherapy, oncology, GLP-1 agonist, obesity, RSV, influenza, oral vaccines, Oral GLP-1, metabolic conditions, Artificial Intelligence, and AI
Locations
-
Primary
Get directions
Queen Mary BioEnterprises Innovation Centre, 42 New Road
London, E1 2AX, GB
-
Get directions
Fitzwilliam Hall, Fitzwilliam Place
4th Floor
Dublin 2, D02 T292, IE
Employees at Poolbeg Pharma plc
-
Eddie Gibson
Associate at Wickenstones Ltd
-
Jeremy Skillington, PhD
Chief Executive Officer at Poolbeg Pharma
-
Brendan Buckley
Chief Medical Officer at Teckro
-
Cathal Friel
Chairman and Co-Founder at Open Orphan Plc (now hVIVO plc) & Poolbeg Pharma Plc, Co-Founder & Director at European Green Transition, Co-Founder of…
Updates
-
Reminder 🚨 we will be presenting at this year's Mello Events 2024 annual in-person event on Wednesday 22 May in Chiswick, London. Join us to learn more about how Poolbeg Pharma plc is positioned to generate value for shareholders, while addressing significant unmet medical needs. Register to attend: https://lnkd.in/eTukhCRE #POLB #POLBF #MelloMonday #MelloEvent
-
We at Poolbeg Pharma plc are deeply moved by our Chief Legal Officer John McEvoy's post on the story of Ruby. We share the commitment to improving the lives of those affected by rare and orphan diseases. Stories like Ruby’s inspire us to continue our mission and deliver on the development and commercialisation of innovative medicines that address critical unmet needs. We hope you join us in helping to raise awareness around CDG and other patients who suffer with rare diseases. #CDGgoGreen #RareDisease #POLB #RareDiseaseAwareness
Executive Chairman - Duality Healthcare Group. SVP, Chief Legal Officer Poolbeg Pharma Plc. Former Global General Counsel at Amryt Pharma Plc. Life Sciences Lawyer of the Year 2023. GC Powerlist - Legal 500 2022 & 2023.
A few weeks ago, a former colleague Steven McCann and his lovely wife asked my wife and I, if we would like to pop into Great Ormond Street Hospital for Children NHS Foundation Trust to visit his beautiful daughter Ruby. Ruby was diagnosed in January with Congenital Disorders of Glycosylation (CDG), a group of extremely rare and complex genetic, metabolic diseases, which affects all parts of the body. Having worked in rare disease for a number of years now, most recently with Amryt Pharma and now Poolbeg Pharma plc, getting to meet patients, especially little kids, who suffer with rare and orphan diseases has always been, and continues to be, truly the most humbling of experiences. As you can see from the photos below, visiting little Ruby was no exception - it was an honour to spend time with her. In the midst of a career and family life, its all too easy to take your eye off the ball or blame a busy schedule for not doing more for these little warriors who fight these terrible conditions on a daily basis. I fear I am guilty more than most for posting business or achievement related content on LinkedIn(!), however, visiting little Ruby has made me more determined to use this platform to try and raise more awareness for those who suffer with rare diseases - especially CDG. Rare diseases can't wait, and people living with rare diseases are taking action to accelerate the diagnostic process and spark research into new potential therapies. We have a plan in place to change the conversation around rare diseases and need your help! 🙏 On Thursday 16th May, I am wearing GREEN for Ruby - to raise awareness across social media for CDG in the hopes that we can both boost awareness and funding for research into this disease. For those who are able, a donation of whatever is affordable to the #justgiving link below would be hugely appreciated, or indeed just a simple share/repost of the link, or any of the posts on Thursday around CDG, to help raise awareness and support those who suffer with rare disease, especially little Ruby and the many other young people with CDG, would be hugely appreciated! Rare is many. Rare is Strong. Rare is Proud. #CDGgoGreen #RareDisease #PatientAdvocacy #CareAboutRARE #rarediseaseawareness #strengthinunity #inclusionmatters💚💚💚💚💚💚💚 https://lnkd.in/emagek-7
-
-
We look forward to attending the upcoming Biotechnology Innovation Organization Bio International Convention on 3-6 June in San Diego, California. The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe. Meet with the team by connecting via the BIO One-on-One Partnering System: https://lnkd.in/eEDtKaAK #POLB #POLBF #BIOConvention #SanDiego #BIO24
-
We will be presenting at this year's Mello Events 2024 annual in-person event on 22 May at the Clayton Hotels in Chiswick, London. Join us to learn more about how Poolbeg Pharma plc is positioned to generate value for shareholders, while addressing significant unmet medical needs. Register to attend: https://lnkd.in/eTukhCRE #POLB #POLBF #MelloMonday #MelloEvent
-
Did you know the orphan drug market is expected to grow more than twice as fast as the non-orphan market? 📈 Expected to grow from US$170bn in 2023 to US$368bn by 2030 (11.6% CAGR) 💊 Orphan drug sales set to account for 20% of all prescription drug sales by 2026 💡Our leadership team has significant knowledge and expertise in rare and orphan diseases products, and we believe that Poolbeg is well positioned to benefit from these opportunities. #POLB #orphandrugs
-
There are >7,000 rare diseases affecting patients around the world, but due to the low prevalence of these diseases, diagnosis can be difficult and treatments are often unavailable or inadequate. 🎯 There is a strong need for more scientific research to find solutions for these diseases and provide support to the >300 million people living with a #raredisease worldwide. Learn more: https://lnkd.in/emc49iPd
-
Unfortunately, there's no definitive test that can be used to diagnose Behçet's disease. A patient will have to endure several tests to check for signs of the condition, or to help rule out other causes, such as: 💉Blood tests 💧Urine tests 🩺Scans, such as X-rays, a CT scan or an MRI scan 🔪Skin biopsy ☑️Pathergy test Current guidelines state a diagnosis of Behçet's disease can usually be confidently made if a patient has experienced at least 3 episodes of mouth ulcers over the past 12 months and have at least 2 of the most common symptoms. Other potential causes also need to be ruled out before the diagnosis is made.
-
People suffering from #Behçetsdisease can have different #symptoms, however the most common symptom is severe ulcers in the mouth. Slide along to understand the different types of symptoms caused by this rare disease. ⚠️Warning: swipe with caution - graphic medical photos #POLB
-
Want to know more about Behçet’s disease? Genetic Alliance UK have shared a patients story, providing an overview on the severity of this rare disease, highlighting the importance of the need for a cure and effective treatments. https://lnkd.in/gTTcANZ4 #Behçets #BehçetsDisease #POLB $POLBF
Rachael's Story
https://www.youtube.com/